The field of respiratory science is expanding and advancing exponentially with more than 545 million global cases of chronic respiratory diseases and the long term-term impact of the novel COVID-19 virus on lung health.
The partnership between KoKo, LLC and RBC Medical Innovations significantly contributes to these ongoing efforts by expanding the manufacturing of world-renowned diagnostic pulmonary function testing equipment.
As a new company that acquired an existing medical product line, KoKo looked to develop a long-term relationship with a well-established design and manufacturing company that shares similar values of customer centricity, dependability, and quality which are key in driving innovation. RBC Medical Innovations’ experience and success proved to be the perfect match.
The global spirometry and pulmonary function test (PFT) markets are forecast to grow at a compound annual growth rate (CAGR) of 10% and 4% respectively between 2020 and 2025. Through RBC’s proprietary processes and acceleration platforms, KoKo’s industry leading spirometers and plethysmographs will be efficiently manufactured to serve the growing PFT market. The passion of enhancing patient care to improve lives guides both companies, leading to meaningful collaboration and diligent focus on research and development.
“We are very pleased to announce our collaboration with RBC. This partnership stabilizes our supply chain to meet the growing demand for our proven medical devices and will support our innovation of new diagnostic devices for respiratory healthcare.” John Peterson, CEO & President of KoKo, LLC.
“KoKo’s market leading legacy products combined with their pipeline of new innovations promise to positively impact of the lives of millions of patients. We couldn’t be more excited to contributed to KoKo’s continued success.” Carl Mayer, CEO, RBC Medical Innovations.
